摘要
目的 :探讨拓扑替康作为二线药物治疗卵巢上皮癌的疗效及安全性。方法 :经病理证实的卵巢上皮癌 4 0例 ,均可评价疗效和毒副作用。静脉滴注拓扑替康 1.2mg (m2 ·d)30min ,每日 1次 ,连用 5d ,2 1d为 1周期 ,2周期评价疗效。结果 :完全缓解率为 5 .0 % ,部分缓解率为 17.5 % ,总有效率为 2 2 .5 %。主要毒副作用为骨髓抑制 ,非血液学毒性轻微 ,均可耐受。结论 :拓扑替康是治疗卵巢上皮癌的有效的二线药物。
Objective:To evaluate the efficacy and safety profile of topotecan as second-line single agent chemotherapy in epithelial ovarian carcinoma.Methods:Forty patients with pathologically and cytologically confirmed epithelial ovarian carcinoma were studied.All 40 cases were evaluated for both efficacy and safety.Topotecan was given as a 30min intravenous infusion at the dose of 1.2mg/(m2·d) for 5 days and 21 days as a course.Efficacy was evaluated after 2 courses.Results:Complete remission(CR) rate was 5%(2/40),partial remission(PR) rate was 17.5%(7/40) and a total effective rate was 22.5%(9/40).Marrow suppression was the dominate side effect.Non-hematological side effects were slight and tolerable.Conclusion:Topotecan appears as an effective secondline chemotherapeutic agent for epithelial ovarian carcinoma.
出处
《现代妇产科进展》
CSCD
2001年第5期353-355,共3页
Progress in Obstetrics and Gynecology
关键词
拓扑替康
治疗
卵巢癌
Topotecan
Ovarian neoplasms
Treatment outcome
